07.01.13
Nutrition 21, LLC, has launched Nitrosigine, a novel patented source of inositol-stabilized arginine silicate accepted by FDA as a New Dietary Ingredient (NDI). In pre-clinical studies, Nitrosigine has been shown to demonstrate superiority over arginine in blood flow markers and has been shown to affect silicon absorption positively, providing evidence of health benefits applicable to many market categories.
Primary investigator, Dr. James Russell, professor emeritus, Department of Surgery, Metabolic and Cardiovascular Diseases Laboratory at the Alberta Institute for Human Nutrition, University of Alberta, Canada and his colleagues conducted one of the preclinical studies, titled “Metabolic Effects of a Novel Silicate Inositol Complex of the Nitric Oxide Precursor Arginine in the Obese Insulin-resistant JCR:LA-cp Rat.” Their research concluded that the arginine silicate inositol complex is absorbed efficiently, raising plasma arginine levels, and is more biologically effective than arginine hydrochloride. Dr. Russell stated, “Our research has shown significant protective effects of the novel amino acid compound arginine silicate in an animal model of the Metabolic Syndrome with treatment reversing impaired function of the coronary arteries.”
For more information: www.nutrition21.com
Primary investigator, Dr. James Russell, professor emeritus, Department of Surgery, Metabolic and Cardiovascular Diseases Laboratory at the Alberta Institute for Human Nutrition, University of Alberta, Canada and his colleagues conducted one of the preclinical studies, titled “Metabolic Effects of a Novel Silicate Inositol Complex of the Nitric Oxide Precursor Arginine in the Obese Insulin-resistant JCR:LA-cp Rat.” Their research concluded that the arginine silicate inositol complex is absorbed efficiently, raising plasma arginine levels, and is more biologically effective than arginine hydrochloride. Dr. Russell stated, “Our research has shown significant protective effects of the novel amino acid compound arginine silicate in an animal model of the Metabolic Syndrome with treatment reversing impaired function of the coronary arteries.”
For more information: www.nutrition21.com
